BR0114036A - Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv - Google Patents

Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv

Info

Publication number
BR0114036A
BR0114036A BR0114036-1A BR0114036A BR0114036A BR 0114036 A BR0114036 A BR 0114036A BR 0114036 A BR0114036 A BR 0114036A BR 0114036 A BR0114036 A BR 0114036A
Authority
BR
Brazil
Prior art keywords
hiv
antigens
peptides
vaccine compositions
induced antibodies
Prior art date
Application number
BR0114036-1A
Other languages
English (en)
Inventor
Birger Sorensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Publication of BR0114036A publication Critical patent/BR0114036A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PEPTìDEOS DE HIV, ANTìGENOS, COMPOSIçõES DE VACINA, KIT DE IMUNOENSAIO E UM MéTODO PARA DETECTAR ANTICORPOS INDUZIDOS PELO HIV". A presente invenção compreende novos e modificados peptídeos capazes de induzir uma resposta imune específica do HIV-1 sem antagonizar a atividade da célula T citotóxica para alcançar uma vacina profilática e terapêutica eficaz contra o HIV. Os peptídeos baseiam-se nas regiões conservadas de proteínas do HIV gag p17 e p24. Os antígenos na forma livre ou ligada a portador compreendendo pelo menos um dos referidos peptídeos, composições de vacina contendo pelo menos um dos antígenos, kits de imunoensaios e um método para detectar anticorpos, induzidos por HIV ou peptídeos específicos do HIV, usando tais antígenos, são descritos.
BR0114036-1A 2000-09-04 2001-09-03 Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv BR0114036A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
PCT/NO2001/000362 WO2002020554A2 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines

Publications (1)

Publication Number Publication Date
BR0114036A true BR0114036A (pt) 2003-07-22

Family

ID=19911533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114036-1A BR0114036A (pt) 2000-09-04 2001-09-03 Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv

Country Status (20)

Country Link
US (2) US7009037B2 (pt)
EP (2) EP1322665B1 (pt)
JP (2) JP2004508381A (pt)
CN (2) CN101104636A (pt)
AR (2) AR033998A1 (pt)
AT (1) ATE406380T1 (pt)
AU (3) AU8270601A (pt)
BR (1) BR0114036A (pt)
CA (1) CA2421193A1 (pt)
DE (1) DE60135564D1 (pt)
EA (1) EA006308B1 (pt)
ES (1) ES2312465T3 (pt)
HK (1) HK1059940A1 (pt)
HU (1) HUP0303134A3 (pt)
MY (1) MY136081A (pt)
NO (1) NO314588B1 (pt)
NZ (2) NZ535148A (pt)
SK (1) SK287917B6 (pt)
WO (1) WO2002020554A2 (pt)
ZA (1) ZA200301740B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503205A (ja) 2000-02-04 2004-02-05 デューク・ユニバーシティー ヒト免疫不全ウイルスワクチン
EP1922355B1 (en) * 2005-08-26 2009-03-11 Novo Nordisk A/S A method of modifying a macromolecular system
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
AP2857A (en) 2008-09-09 2014-02-28 Celebrity Biogens Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスBionor Immuno As 多量体ペプチド
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
NZ702146A (en) * 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
EP3413926A4 (en) 2016-02-08 2019-10-09 American Gene Technologies International, Inc. HIV VACCINATION AND IMMUNOTHERAPY
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3607072A4 (en) 2017-04-03 2021-01-06 American Gene Technologies International Inc. COMPOSITIONS AND METHODS OF TREATMENT OF PHENYLCETONURISM
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556A (en) * 2021-09-02 2023-03-15 113 Botanicals Ltd Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) * 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) * 1991-06-13 1991-06-13 Replico Medical Ab Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
US6525173B1 (en) 1997-01-02 2003-02-25 Universidade Federal De Minas Gerais Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
GB9703802D0 (en) * 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Also Published As

Publication number Publication date
US20070237783A1 (en) 2007-10-11
EP1878742A2 (en) 2008-01-16
AU2001282706B2 (en) 2007-03-22
JP2004508381A (ja) 2004-03-18
HK1059940A1 (en) 2004-07-23
EP1878742A3 (en) 2008-04-30
HUP0303134A3 (en) 2012-09-28
NO314588B1 (no) 2003-04-14
US7009037B2 (en) 2006-03-07
EA200300336A1 (ru) 2003-08-28
DE60135564D1 (de) 2008-10-09
EP1322665B1 (en) 2008-08-27
WO2002020554A3 (en) 2002-06-13
CN1282656C (zh) 2006-11-01
NZ535148A (en) 2007-06-29
CA2421193A1 (en) 2002-03-14
CN1460111A (zh) 2003-12-03
AR071262A2 (es) 2010-06-09
AU2007202739A1 (en) 2007-07-05
JP2011219481A (ja) 2011-11-04
US20040115615A1 (en) 2004-06-17
MY136081A (en) 2008-08-29
EA006308B1 (ru) 2005-10-27
AR033998A1 (es) 2004-01-21
WO2002020554A2 (en) 2002-03-14
HUP0303134A2 (hu) 2005-03-29
ES2312465T3 (es) 2009-03-01
AU8270601A (en) 2002-03-22
NO20004413L (no) 2002-03-05
AU2007202739B2 (en) 2009-12-03
US7612168B2 (en) 2009-11-03
SK287917B6 (sk) 2012-03-02
SK4022003A3 (en) 2003-09-11
EP1322665A2 (en) 2003-07-02
CN101104636A (zh) 2008-01-16
ATE406380T1 (de) 2008-09-15
ZA200301740B (en) 2004-06-21
NO20004413D0 (no) 2000-09-04
NZ524556A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
BR0008741A (pt) Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
Altfeld et al. Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
Siddappa et al. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
BR0114046A (pt) Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
EP0397129A3 (en) Process for preparing an improved western blot immunoassay
Laurent et al. Cell surface expression of several species of human immunodeficiency virus type 1 major core protein
US5998132A (en) Method and apparatus for detecting cancer, influenza, or HIV based on α-N-acetyl-galactosaminidase detection
Gaedigk-Nitschko et al. Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease
EP1104310A4 (en) EXPRESSION AND CHARACTERIZATION OF HIV-1 ENVELOPE PROTEIN ASSOCIATED WITH LARGELY REACTIVE NEUTRALIZATION ANTIBODY RESPONSE
KR890009415A (ko) 항 비루스성 화합물 및 그 제조방법
Moss et al. In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)
Davis et al. Human immunodeficiency virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
ATE119166T1 (de) An hiv relatierte peptide.
von Hintzenstern et al. Delayed seroconversion to HIV in a hemophiliac
KR880014375A (ko) 다양한 아이소타입 반응의 검출에 기초한 adis 진단지험, 백신 및 혈청요법
BR0302029A (pt) Anticorpo ou um fragmento do mesmo, fragmento de um anticorpo, molécula de ácido nucleico, vetor, célula hospedeira, uso de um anticorpo ou um fragmento do mesmo, composto quìmico, péptìdeo, vacina, kit para estudar infecção por hiv in vivo ou in vitro, peptìdeo isolado, e, método para inibir a ligação de hiv a um co-receptor viral
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
KR910001032A (ko) Hiv-2 변이체
Phelan et al. HTLV-III/LAV particle-associated proteins: I. Virus purification, inactivation and basic characterization
TH65071A (th) เพพไทด์ควบคุม และอนุเคราะห์ hiv แอนติเจน องค์ประกอบวัคซีนชุดสำเร็จรูปอิมมูโนแอสเสย์และวิธีการของการตรวจหาแอนติบอดีที่ถูกชักนำโดย hiv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.